It is well known that c-MET is deregulated in many human cancers including pancreatic cancer [93,94,95,96] and can be activated by genetic mutations, gene amplifications, protein overexpression, or a ligand-dependent autocrine/paracrine signaling loop [97,98,99]. This evidence concerns the gene MET and cancer.